Your session is about to expire
← Back to Search
Senolytic
Dasatinib + Quercetin for Premature Aging in Mental Illness
Phase 2
Recruiting
Led By Eric Lenze, MD
Research Sponsored by Washington University School of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10 weeks
Awards & highlights
Summary
This trial will study if two drugs can slow aging in people with depression or schizophrenia.
Who is the study for?
This trial is for people aged 50+ with schizophrenia or 60+ with treatment-resistant major depression. Participants must have three aging-related conditions like hypertension, diabetes, or arthritis, and be on stable medication for their mental disorder. They can't join if they have dementia, recent severe illnesses (like heart attacks), uncontrolled health issues (high blood pressure/diabetes), certain drug interactions, or are at risk of harming themselves.
What is being tested?
The study tests a combination of dasatinib plus quercetin in older adults with depression or schizophrenia to see if it slows down aging. It's an open-label pilot study where everyone knows what treatment they're getting.
What are the potential side effects?
Possible side effects from dasatinib include fluid retention, bleeding problems, and immune system effects; quercetin may cause headaches and tingling in the arms/legs. The combination could potentially amplify these effects.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 10 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of participants who successfully completed and safely tolerated the intervention
Trial Design
1Treatment groups
Experimental Treatment
Group I: Dasatinib + quercetinExperimental Treatment1 Intervention
open label dasatinib plus quercetin combined as a drug therapy
Find a Location
Who is running the clinical trial?
Washington University School of MedicineLead Sponsor
1,970 Previous Clinical Trials
2,308,583 Total Patients Enrolled
UConn HealthOTHER
212 Previous Clinical Trials
60,749 Total Patients Enrolled
Eric Lenze, MDPrincipal InvestigatorWashington University School of Medicine, Department of Psychiatry
9 Previous Clinical Trials
3,416 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I cannot take dasatinib or quercetin due to health reasons.I have at least three age-related conditions like high blood pressure, heart or lung disease.I have never been diagnosed with dementia.I am not on strong CPY3A4 drugs, drugs causing cell aging, or drugs interacting with quercetin.I have major depression that hasn't improved with at least 2 treatments, or I have schizophrenia/schizoaffective disorder.I am over 50 years old, or over 60 if my condition is depression.I am on a stable medication regimen for my schizophrenia, schizoaffective disorder, or depression.My health conditions and medications do not conflict with the study's requirements.
Research Study Groups:
This trial has the following groups:- Group 1: Dasatinib + quercetin
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger